The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set ...

With its new serum, the medical grade skin care brand is targeting laxity, which many weight loss drug users experience.

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...

People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new Canadian study reported Tuesday.

Caution is needed until the harms are better understood Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising treatment for obesity and diabetes. Over the past few years, ...